Chindex revenues increase 21% to $55.5M in second quarter 2014

Chindex International, Inc. (NASDAQ: CHDX), an American healthcare company providing premium quality healthcare services in China through the operations of United Family Healthcare ("UFH"), a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the second quarter ended June 30, 2014.

Second Quarter 2014 Financial Highlights

• Revenue from healthcare services increased 21% to $55.5 million from $46.0 million in the prior year period.
• Adjusted EBITDA increased 42% to $10.3 million from $7.3 million in the prior year period.
• Income from operations decreased 3% to $1.8 million from $1.9 million in the prior year period.
• Net loss was $693,000, or $(0.04) per diluted share, compared to net loss of $122,000, or $(0.01) per diluted share, in the prior year period.
• Merger transaction expenses were $2.0 million.

Roberta Lipson, President and CEO of Chindex, commented, "The second quarter was characterized by continued expansion of our network of hospitals and clinics, and broadening of our scope of services. The United Family Healthcare Financial Street Clinic opened in May 2014, representing our first facility in western Beijing. Along with our Haidian hospital, which is currently under construction, this is part of our focused effort to reach more patients in Beijing's finance and technology centers."

"Our results this quarter reflect substantial development expenses from these expansion activities as well as expenses related to our pending merger. We are continuing our efforts to strategically expand our network and service scope to bring international-standard, premium healthcare services to more people in China," concluded Ms. Lipson.

Business Updates

As previously announced, the Company has entered into an amended and restated merger agreement (the "Amended Agreement") with a buyer consortium (the "Buyer Consortium") comprised of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Ms. Lipson and a merger subsidiary. Pursuant to the Amended Agreement, at the effective time of the merger, the Company will become privately owned and unaffiliated stockholders will be entitled to receive merger consideration of $24.00 per share. As previously announced, the merger is not subject to a financing condition and, assuming the satisfaction of conditions specified in the Amended Agreement, the Company expects the merger to close in the second half of 2014.

Second Quarter 2014 Financial Results

Second quarter 2014 revenue from healthcare services increased 21% to $55.5 million from $46.0 million in the prior year period. These results reflect growth of inpatient and outpatient volume across the United Family Healthcare network as well as increased contributions from the Company's new facilities in Beijing. Overall, outpatient services contributed 57% of revenue while inpatient services contributed 43%, compared with 58% and 42%, respectively, in the prior year period. By service line, surgical services contributed 22.5%; OB/GYN contributed 13.4%; pediatrics contributed 8.2%; ancillary services, including laboratory, radiology and pharmacy, contributed 27.7%; internal medicine contributed 3.4%; emergency room contributed 2.9%; dental contributed 2.8%; family medicine 2.2% and other clinical service lines contributed 16.9% of revenue.

Operating expenses in the second quarter 2014 increased 22% to $53.6 million from $44.1 million in the prior year period. The increase was primarily driven by salaries, wages and benefits expenses, which increased 15% over the second quarter 2013 from $26.8 million to $30.8 million, and merger transaction expenses of $2.0 million, which include fees for legal and other professional services related to the Company's pending merger. The increase in salaries, wages and benefits reflects both an increase in headcount to support revenue growth and development activities for new facilities and services and a new government mandate on increased social benefits. Development, pre- and post-opening and start-up expenses were $3 million, the same as in the prior year period. These expenses were driven by development projects, including expansion of the outpatient clinics at Beijing United Family Hospital and construction of new hospitals in Beijing and Qingdao.

Adjusted EBITDA in the second quarter of 2014 increased 42% to $10.3 million, compared to $7.3 million in the prior year period. The Adjusted EBITDA results show continued growth of the Company's core primary care business as well as growth from recently-expanded surgical services.

Income from operations was $1.8 million, compared to $1.9 million in the prior year period.

The Company recorded a $2.2 million provision for taxes in the second quarter of 2014, compared to the tax provision of $1.7 million in the prior year period. As in past quarters, the current period provision continued to be impacted by a higher tax rate due to losses in development and start-up entities for which the Company cannot currently recognize tax benefits.

Net loss for the quarter ended June 30, 2014 was $693,000, or $(0.04) per diluted share, compared to net loss of $122,000, or $(0.01) per diluted share, in the prior year period. The Company's minority interest in CML represented a loss of $174,000 during the recent period compared to a loss of $387,000 in the prior year period. For the second quarter of 2014, weighted average diluted shares outstanding were 17.8million.

As of June 30, 2014, the Company had $39.3 million in unrestricted cash and cash equivalents.

First Half 2013 Financial Results

During the first half of 2014, revenue from healthcare services increased 20% to $105.3 million from $87.5 million in the prior year period, reflecting growth of inpatient and outpatient volume across the United Family Healthcare network as well as increased contributions from the Company's new facilities in Beijing. Outpatient services contributed 58% of revenue and inpatient services contributed 42% of revenue in the first half of 2014, which represents the same distribution as in the first half of 2013. By service line, surgical services contributed 20.6%, OB/GYN contributed 13.8%, pediatrics contributed 9.0%, ancillary services contributed 28.0%, internal medicine contributed 3.3%, emergency room contributed 2.9%, dental contributed 3.0%, family medicine 2.2% and other services contributed 17.2% of revenue.

Operating expenses for the first half of 2014 increased 26% to $105.0 million from $83.1 million in the prior year period. Development, pre-opening and start up expenses increased to $7.0 million from $5.4million in the prior year. Income from operations for the first half of 2014 was $374,000, compared to $4.5 million in the prior year period. This decrease largely reflects the $5.3 million in merger transaction expenses incurred in the first half of 2014 as compared to $192,000 in merger transaction expenses in the prior year period. Adjusted EBITDA was approximately $19.4million compared to $14.7 million in the prior year period. The Adjusted EBITDA results show continued growth of the Company's core primary care business as well as growth from recently-expanded surgical services.

Provision for taxes was $3.8 million, compared to $3.6 million in the prior year period. Net loss was $4.2 million, or $(0.24) per diluted share, compared to net loss of $184,000, or $(0.01) per diluted share, in the first half of 2013. For the first half of 2014 ended June 30, 2014, weighted average diluted shares outstanding were 17.8million.

Chindex Medical Limited

For Chindex Medical Limited (CML), a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Chindex International, Chindex recognized its 30% interest in CML's net loss using the equity method of accounting since the acquisition of Alma Lasers, Inc. on May 27, 2013.

In the second quarter of 2014, Chindex recognized a loss of $174,000 for its equity interest in CML. For the first half of 2014, the Company recognized a loss of $524,000 million for its equity interest in CML.

The operating results of CML in the first half of 2014 continued to be negatively impacted by the overall slowdown in the capital medical equipment markets in China as a result of restructuring at the Ministry of Finance, uncertainty surrounding proposed reforms and the disruption to normal hospital purchasing activity due to the government campaign to improve compliance in the public hospitals' purchasing activities.

Non-GAAP Measures

The Company presents Adjusted EBITDA to better illustrate ongoing operational results. Adjusted EBITDA is defined as income (loss) before interest expense, interest and other income, income taxes, depreciation and amortization, and also excludes development, pre-opening and start-up expenses related to new and pending hospitals and clinics and equity in earnings (loss) of unconsolidated affiliate and nonrecurring transaction costs. The Company anticipates recurring development, pre-opening and start-up expense and notes that such expense is a basic element of the long term growth plan. Management believes that providing an Adjusted EBITDA analysis to investors is a helpful metric to better illustrate the Company's operations, including development plans, and changes in presentation from historical periods. The Company uses Adjusted EBITDA for business planning and other purposes. Other companies may calculate Adjusted EBITDA differently, and therefore Chindex's Adjusted EBITDA may not be comparable to similarly titled measures of other companies. Adjusted EBITDA is not a measure of financial performance under U.S. generally accepted accounting principles (GAAP), and should not be considered in isolation or as an alternative to net income (loss), cash flows from operating activities and other measures determined in accordance with GAAP. Items excluded from Adjusted EBITDA are significant and necessary components to the operations of the Company's business, and, therefore, Adjusted EBITDA should only be used as a supplemental measure of operating performance.

SOURCE Chindex International, Inc.